Fujifilm to begin clinical trials testing Avigan in COVID-19 patients in Kuwait

pharmafile | July 21, 2020 | News story | Manufacturing and Production COVID-19, Fujifilm, Japan, avigan, coronavirus 

Fujifilm will begin clinical trials investigating the effectiveness of Avigan in treating coronavirus patients in Kuwait.

The trials will be conducted in collaboration with Dr. Reddy’s Laboratories Ltd, from India, and will involve 1,000 people to investigate if the flu drug can work as a treatment for COVID-19.

Earlier this month, Fujifilm said it had granted Dr. Reddy’s exclusive rights to develop, produce and sell Avigan as a potential coronavirus treatment overseas in combination with Global Response Aid.

The trial was originally supposed to be conducted in Japan, and was designed to involve 96 people through late March to June. The trial reportedly ran out of patients, putting an end to the plans of Prime Minister Shinzo Abe who hoped to widely use the drug as a COVID-19 treatment.

Kuwait has had double the amount of coronavirus cases compared to Japan so it is hoped there will be a steadier stream of participants in the study who have the virus. If the trial proves successful, Fujifilm will use the data to show the treatment can be used in Japan.

Avigan (favipiravir) is an antiviral medication largely used to treat influenza in Japan. It was approved in the country in 2014 and became a generic drug in 2019.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content